-+ 0.00%
-+ 0.00%
-+ 0.00%

Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041

Benzinga·08/11/2026 21:01:42
Listen to the news
  • MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026
  • MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectively
  • Data Presented at ATS Showed Molgramostim Demonstrated Continuous Long-term Improvements in Lung Function and Respiratory Health-Related Quality of Life
  • European and Australian Patent Offices Granted MOLBREEVI Liquid Formulation Patents, Providing Protection until March 2041